Status:
NOT_YET_RECRUITING
Towards a Targeted Ultrasound Neuromodulation Intervention for Alcohol Abuse Disorders
Lead Sponsor:
University of Plymouth
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
21-60 years
Phase:
NA
Brief Summary
This study explores the potential of transcranial ultrasound stimulation (TUS) as an innovative therapeutic approach for individuals with Alcohol Use Disorder. By targeting specific brain regions asso...
Detailed Description
Alcohol Use Disorder (AUD) is a prevalent and highly debilitating condition characterized by compulsive alcohol consumption, loss of control over drinking behavior, and significant impairment in socia...
Eligibility Criteria
Inclusion
- Inclusion Criteria will be:
- Male or female, aged 21-55 years, and fluent English speaking.
- Participants score ≥ 20 on the AUDIT.
- Participant is willing and able to give informed consent for participation in the trial.
- Participant is willing to comply with all trial requirements and committed to participating in all six testing sessions.
- Exclusion Criteria will be:
- The participant may not enter the trial if ANY of the following apply.
- History:
- serious head trauma or brain surgery
- (first-degree relatives with) epilepsy, convulsion, or seizure
- diagnosis of a neurological or psychiatric disorder (other than AUD)
- adverse reactions to non-invasive brain stimulation
- participation in another short-term non-invasive brain stimulation study in the past 3 days
- participation in another long-term non-invasive brain stimulation study in the past 28 days
- recent head trauma that was diagnosed as a concussion or associated with loss of consciousness
- Current:
- pregnancy or planning a pregnancy during the course of the trial
- use of psychoactive drugs or any drugs listed in the Neurostimulation Safety Report
- heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement
- metal in the head or body
- claustrophobia
- extreme mood fluctuations
- predisposition to fainting spells (syncope)
- medication that will interfere with the study or constitutes an increased risk of adverse effects (e.g., affects brain excitability)
- hearing problems or ringing in the ears
- skin diseases or sensitivity at intended TUS stimulation site
- Any significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Last 24 hours:
- more than four alcoholic units
- recreational psychoactive drugs
- antibiotics
Exclusion
Key Trial Info
Start Date :
April 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 20 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06894966
Start Date
April 20 2025
End Date
September 20 2026
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Health
Plymouth, Devon, United Kingdom, PL4 8AA